SCHEMBL14924035

SCHEMBL14924035

CCN1CCN(C(C)c2ccc(C(C)C)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.52
MC4R P32245 2/20 0.46
CHRM2 P08172 2/20 0.43
CHRM1 P11229 2/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM2B Q8NHM5 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
RAD52 P43351 1/20 0.41
GFER P55789 1/20 0.41
HTR6 P50406 2/20 0.40
CHRNA7 P36544 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18403964 0.89 GAA (0.54) CYP2D6MC4RCHRM2CHRM1ALDH1A1
SCHEMBL14924473 0.87 ALDH1A1 (0.53) CYP2D6MC4RCHRM2CHRM1ALDH1A1
SCHEMBL18403967 0.87 ALDH1A1 (0.53) CYP2D6MC4RCHRM2CHRM1ALDH1A1
SCHEMBL10112423 0.86 CYP2D6 (0.50) CYP2D6MC4RCHRM2CHRM1SMN1; SMN2
SCHEMBL19251271 0.86 CYP2D6 (0.48) CYP2D6MC4RCHRM2CHRM1ALDH1A1
SCHEMBL20012737 0.85 CYP2D6 (0.74) CYP2D6MC4RCHRM2CHRM1ALDH1A1
SCHEMBL14600336 0.85 CYP2D6 (0.74) CYP2D6MC4RCHRM2CHRM1ALDH1A1
SCHEMBL24129459 0.82 CYP2D6 (0.44) CYP2D6MC4RCHRM2CHRM1ALDH1A1
SCHEMBL13380751 0.80 ATM (0.51) CYP2D6MC4RCHRM2CHRM1ALDH1A1
SCHEMBL24322973 0.79 CYP2D6 (0.53) CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 US disclosed
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2016-08-11 US disclosed
US-9345719-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2016-05-24 US disclosed
US-8957065-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD (KR) 2015-02-17 US disclosed
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2015-02-12 US disclosed
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD. (KR) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, LTK, FYN CYP2D6 4459/4885MC4R 4389/4885CHRM2 4857/4885
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 CYP2D6 4505/4885MC4R 4348/4885CHRM2 4852/4885
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 CYP2D6 4505/4885MC4R 4348/4885CHRM2 4852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.